Hemophilia does not yet have a definitive, permanent cure, but gene therapy has brought treatment closer to that goal than ever before. The FDA approved the first gene therapy for hemophilia B in November 2022, and a gene therapy for hemophilia A followed. These one-time infusions can raise clotting factor levels enough that many patients stop needing regular treatment for years, though questions about lifelong durability remain.
What Gene Therapy Does
Hemophilia is caused by a faulty gene that fails to produce enough of the proteins your blood needs to clot. In hemophilia A, the missing protein is clotting factor VIII. In hemophilia B, it’s factor IX. Traditional treatment involves infusing the missing factor into the bloodstream on a regular schedule, sometimes multiple times per week, to prevent dangerous bleeding episodes.
Gene therapy takes a fundamentally different approach. Instead of replacing the missing protein over and over, it delivers a working copy of the gene itself into liver cells, which then begin manufacturing the clotting factor on their own. The delivery vehicle is a harmless, engineered virus (called an adeno-associated virus) that carries the corrected gene into the liver. Once inside, the gene stays active in those cells without integrating into your chromosomes, functioning as a separate piece of DNA that instructs the liver to produce clotting factor continuously.
How Well Gene Therapy Works
For hemophilia B, clinical trial data out to five years shows strong, sustained results. Patients who received gene therapy saw their factor IX activity rise to an average of about 41% of normal in the first year and maintain at roughly 46% by year five. Normal factor IX activity is 50 to 150%, so these patients moved from severe hemophilia into the mild range or even near-normal levels. Their average annual bleeding rate dropped to 0.14 over five years, meaning most patients experienced no bleeds at all. Two out of three participants in the phase 2b trial had zero bleeds across the entire five-year follow-up period.
For hemophilia A, the picture is promising but more variable. Five years after treatment, the average factor VIII activity level was about 30% of normal. That’s well above the threshold for severe hemophilia (less than 1%) and enough to significantly reduce bleeding, but the wide range of individual responses and a gradual decline in factor levels over time raise questions about how long the benefit will last.
Quality of life improves meaningfully after gene therapy. In one trial for hemophilia B, patients reported significant gains in physical health, the ability to perform complex physical activities, and overall well-being within a year of treatment. More than 56% of participants said their overall experience of living with hemophilia had “greatly improved.”
Why It’s Not Considered a Permanent Cure
The corrected gene delivered by gene therapy doesn’t become a permanent part of your DNA. It sits inside liver cells as a separate loop of genetic material. Over time, as liver cells naturally turn over and die, some of that genetic material is lost. This is likely why factor levels gradually decline in some patients. Whether the effect lasts 10, 20, or 50 years is something researchers simply don’t know yet, because the therapies haven’t existed long enough to tell.
There’s also the question of re-dosing. Your immune system builds antibodies against the virus used to deliver the gene. That means if factor levels eventually drop too low, you can’t simply get another infusion of the same therapy. Your body would neutralize it before it reached the liver. People who already have antibodies to these viruses from natural exposure may not be eligible for gene therapy in the first place.
Monitoring After Treatment
Gene therapy isn’t a single appointment and done. Because the therapy targets the liver, there’s a risk of liver inflammation in the weeks and months afterward. Patients need regular blood tests to check liver enzyme levels, and if those enzymes rise even modestly (about 1.5 times above baseline), doctors will start a course of steroids to tamp down the immune response before it damages the liver or destroys the therapeutic gene. Liver ultrasounds every six months are also recommended to watch for any longer-term effects.
This monitoring period can last months, and the steroid treatment itself comes with side effects that need to be managed. It’s a real commitment, and it’s one reason gene therapy requires careful patient selection and close follow-up rather than being a simple one-and-done procedure.
The Cost Barrier
Gene therapy for hemophilia carries a staggering price tag. The hemophilia B gene therapy has a list price of $3.5 million for a single dose. The logic behind the pricing is that it replaces decades of factor replacement therapy, which can cost hundreds of thousands of dollars per year. Over a lifetime, gene therapy could theoretically save money. But paying that amount upfront creates enormous challenges for patients, insurers, and health systems.
Health economists have recommended that insurers and manufacturers develop outcomes-based agreements, essentially payment models where the final cost depends on how well the therapy actually works for each patient over time. These models are still being developed, and access remains uneven.
Standard Treatment Still Works
For people who aren’t candidates for gene therapy, or who choose not to pursue it, current standard care is highly effective. Regular prophylactic infusions of clotting factor, sometimes supplemented by newer long-acting therapies that reduce how often you need treatment, can prevent the vast majority of bleeding episodes and allow a near-normal life. Gene therapy offers freedom from that infusion schedule, but it’s not the only path to managing hemophilia well.
What’s on the Horizon
Researchers are working on gene editing techniques that could go a step further than current gene therapy. Instead of delivering a corrected gene that sits outside your chromosomes, these approaches would fix the mutation directly in your DNA, potentially making the correction permanent. One method called base editing has shown the ability to correct common hemophilia A mutations in laboratory and early experimental models. Similar gene editing tools are already in clinical trials for other blood disorders like sickle cell disease, which suggests hemophilia-specific trials could follow. If successful, this approach would address the durability problem that limits current gene therapies.